InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

Priming tumor microenvironment with regimen,killing cancer cells and consolidating treatment via specified therapy
Asset | Modality / Target | Regimen | Indication | Discovery | Pre-Clinical | FIH | POC | Pivotal |
---|---|---|---|---|---|---|---|---|
IN10018 Small molecular FAK inhibitor | + PLD | PROC (double-blind, placebo controlled, randomized study) |
|
|||||
+ MEKi ± IO | IO-failed NRAS melanoma Uveal melanoma |
|
||||||
+ PLD ± IO | PROC, TNBC, HNSCC |
|
||||||
+ chemotherapy + IO | IO-failed NSCLC (randomized study) |
|
||||||
+ chemotherapy + IO bispecific | Pancreatic cancer |
|
||||||
+ KRASG12C inhibitor | KRASG12CCRC and NSCLC |
|
||||||
+3rd EGFR inhibitor | EGFR mutant NSCLC |
|
||||||
OMTX705 | ADC Targeting FAP | Mono / Combo | Solid Tumor |
|
||||
INES103 | Antibody Target undisclosed | Combo | Solid Tumor |
|
||||
IN30718 | ADC Target undisclosed | Mono | Solid Tumor |
|
||||
IN30728 | ADC Target undisclosed | Mono | Solid Tumor |
|
||||
IN20019 | Small molecular Target undisclosed | Mono | Solid Tumor |
|
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.